Clinical application of expectorant therapy in chronic inflammatory airway diseases (Review)

Zhang,Ting; Zhou,Xiangdong

doi:10.3892/etm.2014.1494

Clinical application of expectorant therapy in chronic inflammatory airway diseases (Review)

Authors:
- Ting Zhang
- Xiangdong Zhou
View Affiliations

Affiliations: Department of Respiratory Medicine, The Second Affiliated Hospital, Chongqing Medical University, Chongqing 400010, P.R. China
Published online on: January 21, 2014 https://doi.org/10.3892/etm.2014.1494
Pages: 763-767

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Airway mucus hypersecretion is a significant clinical and pathological feature of chronic inflammatory airway diseases. Its clinical presentations include recurrent coughing and phlegm. Airway mucus is closely associated with the occurrence, development and prognosis of chronic inflammatory airway diseases and critically affects the lung function, quality of life, hospitalization rate and mortality of patients with chronic inflammatory airway diseases. Therefore, expectorant therapies targeting the potential mechanisms of mucus hypersecretion have been the focus of numerous studies. Conventional expectorants are mainly mucoactive medicines, including nausea‑stimulating expectorants, mucolytics, mucokinetics, and proteases and nucleases. In addition, certain traditional Chinese herbal medicines and non‑mucoactive agents, including muscarinic acetylcholine receptor antagonists, corticosteroids, leukotriene receptor antagonists and macrolide antibiotics, have also shown expectorant effects. Several novel medicines for expectorant therapy have emerged, including cholesterol‑lowering statins, epidermal growth factor receptor tyrosine kinase inhibitors, phosphodiesterase‑4 inhibitors, stanozolol, surfactants, flavonoids, tachykinin receptor antagonists, protease inhibitors, cytokine antagonists and purinergic agonists. With the increasing number of multidisciplinary studies, the effectiveness of expectorant therapy for the treatment of chronic inflammatory airway diseases has been confirmed. Therefore, the development of novel expectorants and the standardization of expectorant therapy are the direction and focus of future studies, thus benefiting patients who have a chronic inflammatory airway disease.

View Figures

View References

1	Lundgren JD and Shelhamer JH: Pathogenesis of airway mucus hypersecretion. J Allergy Clin Immunol. 85:399–417. 1990. View Article : Google Scholar : PubMed/NCBI
2	Rogers DF: Mucus hypersecretion in chronic obstructive pulmonary disease. Novartis Found Symp. 234:65–83. 2001. View Article : Google Scholar : PubMed/NCBI
3	Zhou X, Tong J and Lan J: Chronic obstructive pulmonary disease airway mucin molecular phenotypic studies. Chin J Tuberc Respir Dis. 25:437–441. 2002.(In Chinese).
4	Vestbo J: Epidemiological studies in mucus hypersecretion. Novartis Found Symp. 248:3–19. 277–282. 2002. View Article : Google Scholar : PubMed/NCBI
5	Rogers DF: Physiology of airway mucus secretion and pathophysiology of hypersecretion. Respir Care. 52:1134–1149. 2007.PubMed/NCBI
6	Davis CW and Dickey B: Regulated airway goblet cell mucin secretion. Annu Rev Physiol. 70:487–512. 2008. View Article : Google Scholar : PubMed/NCBI
7	Rogers DF: Airway mucus hypersecretion in asthma: an undervalued pathology? Curr Opin Pharmacol. 4:241–250. 2004. View Article : Google Scholar : PubMed/NCBI
8	Cerveri I and Brusasco V: Revisited role for mucus hypersecretion in the pathogenesis of COPD. Eur Respir Rev. 19:109–112. 2010. View Article : Google Scholar : PubMed/NCBI
9	Burgel PR and Martin C: Mucus hypersecretion in COPD: should we only rely on symptoms? Eur Respir Rev. 19:94–96. 2010. View Article : Google Scholar : PubMed/NCBI
10	Lai H and Rogers DF: New pharmacotherapy for airway mucus hypersecretion in asthma and COPD: targeting intracellular signaling pathways. J Aerosol Med Pulm Drug Deliv. 23:219–231. 2010. View Article : Google Scholar : PubMed/NCBI
11	Rogers DF: Mucoactive agents for airway mucus hypersecretory diseases. Respir Care. 52:1176–1197. 2007.PubMed/NCBI
12	Henke MO, Shah SA and Rubin BK: The role of airway secretions in COPD - clinical applications. COPD. 2:377–390. 2005. View Article : Google Scholar : PubMed/NCBI
13	Disse B: Clinical evaluation of new therapies for treatment of mucus hypersecretion in respiratory diseases. Novartis Found Symp. 248:254–276. 277–282. 2002. View Article : Google Scholar : PubMed/NCBI
14	Evans CM and Koo JS: Airway mucus: the good, the bad, the sticky. Pharmacol Ther. 121:332–348. 2009. View Article : Google Scholar : PubMed/NCBI
15	Voynow JA and Rubin BK: Mucins, mucus, and sputum. Chest. 135:505–512. 2009. View Article : Google Scholar : PubMed/NCBI
16	Morcillo EJ and Cortijo J: Mucus and MUC in asthma. Curr Opin Pulm Med. 12:1–6. 2006. View Article : Google Scholar : PubMed/NCBI
17	de Marco R, Accordini S, Cerveri I, et al: Incidence of chronic obstructive pulmonary disease in a cohort of young adults according to the presence of chronic cough and phlegm. Am J Respir Crit Care Med. 175:32–39. 2007.PubMed/NCBI
18	Vestbo J and Hogg JC: Convergence of the epidemiology and pathology of COPD. Thorax. 61:86–88. 2006. View Article : Google Scholar : PubMed/NCBI
19	Delmotte P, Degroote S, Lafitte JJ, et al: Tumor necrosis factor alpha increases the expression of glycosyltransferases and sulfotransferases responsible for the biosynthesis of sialylated and/or sulfated Lewis × epitopes in the human bronchial mucosa. J Biol Chem. 277:424–431. 2002.
20	Hogg JC, Chu FS, Tan WC, et al: Survival after lung volume reduction in chronic obstructive pulmonary disease: insights from small airway pathology. Am J Respir Crit Care Med. 176:454–459. 2007.PubMed/NCBI
21	Rogers DF and Barnes PJ: Treatment of airway mucus hypersecretion. Ann Med. 38:116–125. 2006. View Article : Google Scholar
22	Barnes PJ: Current and future therapies for airway mucus hypersecretion. Novartis Found Symp. 248:237–253. 277–281. 2002. View Article : Google Scholar : PubMed/NCBI
23	Lun Z: The market analysis of Ambroxol in China. Chinese Pharmaceutical Information. 22:23–26. 2006.(In Chinese).
24	Beeh KM, Beier J, Esperester A and Paul LD: Antiinflammatory properties of ambroxol. Eur J Med Res. 13:557–562. 2008.PubMed/NCBI
25	Malerba M and Ragnoli B: Ambroxol in the 21st century: pharmacological and clinical update. Expert Opin Drug Metab Toxicol. 4:1119–1129. 2008. View Article : Google Scholar : PubMed/NCBI
26	Dekhuijzen PN and van Beurden WJ: The role for N-acetylcysteine in the management of COPD. Int J Chron Obstruct Pulmon Dis. 1:99–106. 2006.PubMed/NCBI
27	Sadowska AM, Manuel-Y-Keenoy B and De Backer WA: Antioxidant and anti-inflammatory efficacy of NAC in the treatment of COPD: discordant in vitro and in vivo dose-effects: a review. Pulm Pharmacol Ther. 20:9–22. 2007. View Article : Google Scholar : PubMed/NCBI
28	Stav D and Raz M: Effect of N-acetylcysteine on air trapping in COPD: a randomized placebo-controlled study. Chest. 136:381–386. 2009. View Article : Google Scholar : PubMed/NCBI
29	Pela R, Calcagni AM, Subiaco S, et al: N-acetylcysteine reduces the exacerbation rate in patients with moderate to severe COPD. Respiration. 66:495–500. 1999. View Article : Google Scholar : PubMed/NCBI
30	Gerrits CM, Herings RM, Leufkens HG and Lammers JW: N-acetylcysteine reduces the risk of re-hospitalisation among patients with chronic obstructive pulmonary disease. Eur Respir J. 21:795–798. 2003. View Article : Google Scholar : PubMed/NCBI
31	Millea PJ: N-acetylcysteine: multiple clinical applications. Am Fam Physician. 80:265–269. 2009.PubMed/NCBI
32	Hooper C and Calvert J: The role for S-carboxymethylcysteine (carbocisteine) in the management of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 3:659–669. 2008.PubMed/NCBI
33	Zheng JP, Kang J, Huang SG, et al: Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study. Lancet. 371:2013–2018. 2008. View Article : Google Scholar : PubMed/NCBI
34	Yasuda H, Yamaya M, Sasaki T, et al: Carbocisteine reduces frequency of common colds and exacerbations in patients with chronic obstructive pulmonary disease. J Am Geriatr Soc. 54:378–380. 2006. View Article : Google Scholar : PubMed/NCBI
35	Tatsumi K and Fukuchi Y; PEACE Study Group. Carbocisteine improves quality of life in patients with chronic obstructive pulmonary disease. J Am Geriatr Soc. 55:1884–1886. 2007. View Article : Google Scholar : PubMed/NCBI
36	Hauber HP and Zabel P: Emerging mucus regulating drugs in inflammatory and allergic lung disease. Inflamm Allergy Drug Targets. 7:30–34. 2008. View Article : Google Scholar : PubMed/NCBI
37	Li G, Cun X, Li L and Yongqing X: Advances in studies on Platycodon grandiflorum. China Journal of Chinese Materia Medica. 32:183–185. 2007.(In Chinese).
38	Bin Y, Yongqing X, Rixin L, Ruojing W, Wen L, Cun Z, Ying C, Qianpeng W, Lan W and Yongyan W: Studies on expectorant compounds in volatile oil from root and rhizome of Aster tataricus. China Journal of Chinese Materia Medica. 33:281–283. 2008.(In Chinese).
39	Haiqing W, Hongwei K, Kang J, Jingli S, Yan L, Jun T and Shiyou Y: Antitussive, expectorant and antibacterial actions of Zhebei Zhike granules. Chinese Journal of Experimental Traditional Medical Formulae. 17:207–210. 2011.(In Chinese).
40	McKay A, Leung BP, McInnes IB, et al: A novel anti-inflammatory role of simvastatin in a murine model of allergic asthma. J Immunol. 172:2903–2908. 2004. View Article : Google Scholar : PubMed/NCBI
41	Weitz-Schmidt G: Statins as anti-inflammatory agents. Trends Pharmacol Sci. 23:482–486. 2002. View Article : Google Scholar
42	Wang HX, Sun B, Li JQ, et al: Effect of simvastatin on airway mucus hypersecretion in rats and its molecular mechanism. Di 3 Jun Yi Da Xue Xue Bao. 30:213–215. 2008.(In Chinese).
43	Søyseth V, Brekke PH, Smith P and Omland T: Statin use is associated with reduced mortality in COPD. Eur Respir J. 29:279–283. 2007.
44	Mancini GB, Etminan M, Zhang B, et al: Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol. 47:2554–2560. 2006. View Article : Google Scholar
45	Kitazaki T, Fukuda M, Soda H and Kohno S: Novel effects of gefitinib on mucin production in bronchioloalveolar carcinoma; two case reports. Lung Cancer. 49:125–128. 2005. View Article : Google Scholar : PubMed/NCBI
46	Kitazaki T, Soda H, Doi S, et al: Gefitinib inhibits MUC5AC synthesis in mucin-secreting non-small cell lung cancer cells. Lung Cancer. 50:19–24. 2005. View Article : Google Scholar : PubMed/NCBI
47	Guan AY, Xu ZB, Wen FQ, Wang BD and Feng Y: Effect of gefinitib on airway mucus hypertension induced by acrolein in rats. Sichuan Da Xue Xue Bao Yi Xue Ban. 39:231–234. 2008.(In Chinese).
48	Vignola AM: PDE4 inhibitors in COPD - a more selective approach to treatment. Respir Med. 98:495–503. 2004. View Article : Google Scholar : PubMed/NCBI
49	Kroegel C and Foerster M: Phosphodiesterase-4 inhibitors as a novel approach for the treatment of respiratory disease: cilomilast. Expert Opin Investig Drugs. 16:109–124. 2007. View Article : Google Scholar : PubMed/NCBI
50	Michalski JM, Golden G, Ikari J and Rennard SI: PDE4: a novel target in the treatment of chronic obstructive pulmonary disease. Clin Pharmacol Ther. 91:134–142. 2012. View Article : Google Scholar : PubMed/NCBI
51	Moretti M, Bottrighi P, Dallari R, et al; EQUALIFE Study Group. The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE Study. Drugs Exp Clin Res. 30:143–152. 2004.PubMed/NCBI
52	Marchioni CF, Polu JM, Taytard A, et al: Evaluation of efficacy and safety of erdosteine in patients affected by chronic bronchitis during an infective exacerbation phase and receiving amoxycillin as basic treatment (ECOBES, European Chronic Obstructive Bronchitis Erdosteine Study). Int J Clin Pharmacol Ther. 33:612–618. 1995.
53	Rhee CK, Kang CM, You MB, Yoon HK, Kim YK, Kim KH, Moon HS, Park SH and Song JS: Effect of fudosteine on mucin production. Eur Respir J. 32:1195–202. 2008. View Article : Google Scholar : PubMed/NCBI
54	Xin S, Yi S, Zenghua X, Yong S and Gui Z: A randomized controlled trial of expectorant in patients with respiratory tract infection. Chinese Journal of New Drugs and Clinical Remedies. 25:369–372. 2006.(In Chinese).
55	Li N, Li Q, Zhou XD, et al: The effect of quercetin on human neutrophil elastase-induced mucin5AC expression in human airway epithelial cells. Int Immunopharmacol. 14:195–201. 2012. View Article : Google Scholar : PubMed/NCBI
56	Wu H, Li Q, Zhou X, et al: Theaflavins extracted from black tea inhibit airway mucous hypersecretion induced by cigarette smoke in rats. Inflammation. 35:271–279. 2012. View Article : Google Scholar : PubMed/NCBI
57	Kwon SH, Nam JI, Kim SH, et al: Kaempferol and quercetin, essential ingredients in Ginkgo biloba extract, inhibit interleukin-1beta-induced MUC5AC gene expression in human airway epithelial cells. Phytother Res. 23:1708–1712. 2009.PubMed/NCBI
58	Khan S, Liu YC, Khawaja AM, et al: Effect of the long-acting tachykinin NK(1) receptor antagonist MEN 11467 on tracheal mucus secretion in allergic ferrets. Br J Pharmacol. 132:189–196. 2001. View Article : Google Scholar : PubMed/NCBI
59	Shao MX and Nadel JA: Neutrophil elastase induces MUC5AC mucin production in human airway epithelial cells via a cascade involving protein kinase C, reactive oxygen species, and TNF-alpha-converting enzyme. J Immunol. 15:4009–4016. 2005. View Article : Google Scholar
60	Chughtai B and O’Riordan TG: Potential role of inhibitors of neutrophil elastase in treating diseases of the airway. J Aerosol Med. 17:289–298. 2004. View Article : Google Scholar : PubMed/NCBI
61	Feng L, Zhu W, Huang C and Li Y: Direct interaction of ONO-5046 with human neutrophil elastase through ¹H NMR and molecular docking. Int J Biol Macromol. 51:196–200. 2012. View Article : Google Scholar : PubMed/NCBI
62	Tomiyama H, Takara I, Tokumine J and Sugahara K: Sivelestat sodium hydrate was effective for ARDS in a patient suffering from chronic rheumatoid arthritis with acute exacerbation after failing to respond to high dose steroid pulse therapy. Masui. 53:1042–1046. 2004.(In Japanese).
63	Hubeau C, Singer M, Lagranderie M, et al: Extended freeze-dried Mycobacterium bovis Bacillus Calmette-Guérin induces the release of interleukin-12 but not tumour necrosis factor-α by alveolar macrophages, both in vitro and in vivo. Clin Exp Allergy. 33:386–393. 2003.PubMed/NCBI
64	Cheng G, Arima M, Honda K, et al: Anti-interleukin-9 antibody treatment inhibits airway inflammation and hyperreactivity in mouse asthma model. Am J Respir Crit Care Med. 166:409–416. 2002. View Article : Google Scholar : PubMed/NCBI
65	Tomkinson A, Tepper J, Morton M, Bowden A, Stevens L, Harris P, Lindell D, Fitch N, Gundel R and Getz EB: Inhaled vs subcutaneous effects of a dual IL-4/IL-13 antagonist in a monkey model of asthma. Allergy. 65:69–77. 2010. View Article : Google Scholar : PubMed/NCBI
66	Cook ML and Bochner BS: Update on biological therapeutics for asthma. World Allergy Organ J. 3:188–94. 2010.PubMed/NCBI
67	Sabater JR, Mao YM, Shaffer C, et al: Aerosolization of P2Y(2)-receptor agonists enhances mucociliary clearance in sheep. J Appl Physiol (1985). 87:2191–2196. 1999.PubMed/NCBI
68	Yerxa BR, Sabater JR, Davis CW, et al: Pharmacology of INS37217 [P(1)-(uridine 5′)-P(4)- (2′-deoxycytidine 5′)tetraphosphate, tetrasodium salt], a next-generation P2Y(2) receptor agonist for the treatment of cystic fibrosis. J Pharmacol Exp Ther. 302:871–880. 2002.
69	Kellerman DJ: P2Y(2) receptor agonists: a new class of medication targeted at improved mucociliary clearance. Chest. 121(5 Suppl): 201S–205S. 2002. View Article : Google Scholar : PubMed/NCBI
70	Poole P, Black PN and Cates CJ: Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 8:CD0012872012.